• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Telesis Bio Reports Second Quarter 2023 Financial Results

    8/10/23 4:05:00 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TBIO alert in real time by email

    SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the second quarter of 2023.

    "We achieved important milestones this quarter toward our path to profitability by delivering revenue growth again while expanding gross margins and reducing operating expenses. In addition, we raised capital during the quarter to provide us with additional operating runway," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio.

    Highlights

    Strengthened balance sheet and board of directors:

    • Closed a financing that brought in $28 million with the possibility of obtaining an additional $46.2 million if investors cash-exercise their warrants.
    • Appointed Paul Meister, former Chairman of ThermoFisher Scientific and a partner at Novalis LifeSciences LLC, to the Company's board of directors.

    Successful on-time launch of three BioXp® kits:

    • BioXp® Select DNA Cloning Kit enables on-demand and automated assembly of DNA fragments via Gibson assembly® or Golden Gate assembly cloning methods beginning from the customer's linear DNA to streamline and accelerate discovery workflows in mRNA therapeutics, vaccines, and precision medicine.
    • BioXp NGS Library Prep kit for Plasmid Sequencing provides scientists on-demand and automated library preparation of plasmid DNA for use in next-generation sequencing applications. For customers who manufacture plasmid DNA for vaccine, gene therapy, or other R&D applications, it is critical to confirm the quality of the end product through DNA sequencing, but the commonly employed sample preparation methods are time consuming and labor intensive.
    • BioXp De novo DNA Cloning Kit for assembly and cloning of long DNA builds. This kit expands the total length of insert that can be cloned on the instrument and introduces higher throughput 48, 72, and 96 reactions per run for these longer inserts.

    Delivered operational milestones, including:

    • Successfully achieved collaboration milestones and advanced our SOLA technology platform.
    • Vertical integration of manufacturing to produce oligos in-house with a commitment to substantially offset our existing external supply by the end of 2023.
    • Finalized operations necessary to enable in-house manufacturing of our BioXp system in the third quarter.

    The company's expectation is that these insourcing efforts will be substantially completed by year-end and that full financial benefit will be realized in 2024.

    Second Quarter 2023 Financial Results  

    Revenue was $8.7 million for the second quarter 2023, a 53% increase from $5.7 million for the same period in the prior year. This growth was primarily driven by achievement of another collaboration milestone and sales of BioXp systems.

    Gross margins were 65.8% for the second quarter compared to 48% for the same period in the prior year, driven by the completion of a milestone under our agreement with Pfizer and reflecting a positive mix shift in revenue from recently launched products within our growing BioXp portfolio.

    Operating expenses were approximately $13.7 million for the second quarter 2023 compared to $17.2 million for the same period in the prior year. This decrease is primarily a result of ongoing cost-cutting decisions including a reduction in force during the quarter to focus the team on our most profitable and near-term opportunities. This is the fourth consecutive quarter the company has successfully reduced or maintained its operating expenses while growing revenue on a year-over-year basis.

    Net loss was $8.3 million for the second quarter 2023, compared to a loss of $14.8 million in the same period in the prior year. Net loss per share was $0.28 for the second quarter of 2023, compared to $0.50 for the corresponding prior year period.

    Cash, cash equivalents, and investments were $47.5 million as of June 30, 2023.

    Webcast and Conference Call Information

    Company management will host a conference call today, Thursday, August 10, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

    The press release and live audio webcast can be accessed via the Investor section of Telesis Bio's website at ir.telesisbio.com and the conference call can be accessed live by pre-registering here: https://register.vevent.com/register/BI5027491b111b49a6a5d05999b6cf5bb6. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on our website for 30 days.

    About Telesis Bio

    Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity's greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.

    Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio's future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Quarterly Report on Form 10-Q, which was filed with the SEC on May 12, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.

    Contact:

    Jen Carroll

    Vice President of Investor Relations

    [email protected]



    Telesis Bio Inc.

    Selected Statements of Operations Financial Data

    (in thousands, except per share amounts)

    (unaudited)

                
     Three Months Ended 

    June 30,
      Six Months Ended 

    June 30,
     
     2023  2022  2023  2022 
    Revenue:           
    Product sales$2,670  $2,337  $5,671  $4,760 
    Service revenue 1,713   1,755   3,387   3,460 
    Collaboration revenue 3,462   962   4,424   1,924 
    Royalties and other revenue 807   601   1,486   1,147 
    Total revenue 8,652   5,655   14,968   11,291 
    Cost of revenue 2,959   2,943   5,764   5,801 
    Gross Profit 5,693   2,712   9,204   5,490 
    Operating expenses:           
    Research and development 4,587   6,950   9,708   13,255 
    Sales and marketing 3,360   4,688   7,167   8,225 
    General and administrative 5,712   5,561   11,266   11,360 
    Total operating expenses 13,659   17,199   28,141   32,840 
    Loss from operations (7,966)  (14,487)  (18,937)  (27,350)
    Interest expense, net (333)  (299)  (582)  (635)
    Change in fair value of derivative liabilities 19   (27)  159   (4)
    Other expense, net (3)  (12)  (39)  (24)
    Provision for income taxes (4)  (6)  (7)  (12)
    Net loss$(8,287) $(14,831) $(19,406) $(28,025)
    Less: redeemable convertible preferred stock dividends (153)  —   (153)  — 
    Net loss attributable to common stockholders$(8,440) $(14,831) $(19,559) $(28,025)
    Net loss per share, basic and diluted$(0.28) $(0.50) $(0.66) $(0.95)
    Weighted average common stock outstanding—basic and diluted 29,774,275   29,435,838   29,718,948   29,383,870 
     



    Telesis Bio Inc.


    Selected Balance Sheet Financial Data

    (in thousands)

    (unaudited)

     June 30,  December 31, 
     2023  2022 
    Balance Sheet Data:     
    Cash, restricted cash, cash equivalents and short-term investments$47,530  $43,753 
    Working capital 51,157   41,594 
    Total assets 114,526   81,362 
    Total liabilities 58,457   34,797 
    Redeemable convertible preferred stock 28,153   — 
    Accumulated deficit (133,147)  (113,741)
    Total stockholders' equity 27,916   46,565 









    Primary Logo

    Get the next $TBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TBIO

    DatePrice TargetRatingAnalyst
    8/4/2021$45.00 → $38.00Neutral
    Roth Capital
    8/3/2021$19.00 → $38.00Market Perform
    SVB Leerink
    8/3/2021Outperform → Market Perform
    William Blair
    7/26/2021$28.00 → $45.00Buy
    Roth Capital
    More analyst ratings

    $TBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

      Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to the Company of up to approximately $21 million. The Company's recently launched proprietary next-generation enzymatic synthesis platform, Gibson SOLA™, allows customers to take full control of their nucleic acid supply-chain,

      3/18/25 9:00:00 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

      SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio's Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications. The collaboration integrates Telesis Bio's Gibson

      9/25/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

      SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO) ("Telesis" or the "Company"), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, announced today that it has notified the Nasdaq Stock Market LLC ("Nasdaq") of its decision to delist the Company's shares of common stock, par value $0.001 per share (the "Common Stock") and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Telesis intends to file a Form 25 with the Securities and Exchange Commission (the "SEC")

      9/10/24 4:30:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Telesis Bio Inc.

      15-12G - Telesis Bio Inc. (0001850079) (Filer)

      1/14/25 4:35:26 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Telesis Bio Inc.

      EFFECT - Telesis Bio Inc. (0001850079) (Filer)

      1/7/25 12:15:02 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Telesis Bio Inc.

      EFFECT - Telesis Bio Inc. (0001850079) (Filer)

      1/7/25 12:15:03 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TBIO
    Financials

    Live finance-specific insights

    See more
    • Director Krueger Todd was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:07:04 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Golub Steven J was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:06:35 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Hlavinka Sarah E. was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:06:03 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Roth Capital reiterated coverage on Translate Bio with a new price target

      Roth Capital reiterated coverage of Translate Bio with a rating of Neutral and set a new price target of $38.00 from $45.00 previously

      8/4/21 10:08:32 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVB Leerink reiterated coverage on Translate Bio with a new price target

      SVB Leerink reiterated coverage of Translate Bio with a rating of Market Perform and set a new price target of $38.00 from $19.00 previously

      8/3/21 11:37:09 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Translate Bio downgraded by William Blair

      William Blair downgraded Translate Bio from Outperform to Market Perform

      8/3/21 11:20:22 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Telesis Bio Inc.

      SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

      11/8/24 8:23:25 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

      SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

      11/6/24 4:50:27 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

      SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

      11/6/24 4:05:27 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Reports First Quarter 2024 Financial Results

      SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the first quarter of 2024.  In discussing results, recently appointed President and CEO Eric Esser said, "I am pleased with our performance as we execute against our strategy to focus on Gibson SOLA and BioXp mRNA solutions. Our BioXp mRNA offerings continue to gain traction and are delivering real improvements in speed and simplicity to our customers in their discovery workflows. I'm also excited abo

      5/9/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

      SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, "I'm pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin aga

      3/28/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Reports Third Quarter 2023 Financial Results

      SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. "This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengthened board of directors and management team: Appointed Greg Herrema, Senior Advisor to Novalis LifeSciences to the Telesis Bio board of directors in October 2023. Mr. Herrema's distinguished car

      11/13/23 4:22:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

      SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024. Highlights Gibson SOLA – the Company continues to advance its Gibson SOLA reagent platform that enables on-premises automated overnight synthesis of high-fidelity long DNA and mRNA on a variety of liquid handling platforms. The Company's presentation "Enhancing Therapeutic Protein Production with Gibson SOLA Enzymatic DNA Assembly: Pioneeri

      8/7/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • Telesis Bio Appoints William J. Kullback Chief Financial Officer

      SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions. "Bill's deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to help lead us through the next phase of the Company's growth," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. "We are thrilled to welcome Bill to our team and excited to have another lead

      8/29/23 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials